Medical and wellness cannabis operator, Curaleaf recently got warned by the Food and Drug Administration (FDA) for “illegal selling” reports CNBC. Since said warning, Curaleaf revisited both its social media accounts and website to remove any health claims that are reasoned as non-compliant by the agency.
Specifically speaking, the FDA was not pleased to see the “unsubstantiated claims” made in relation to the use of CBD and how the latter can help relieve severe health conditions such as Alzheimer’s disease, anxiety and pain among others.
The CEO of Curaleaf, Joseph Lusardi has since released a statement mentioning that the company will do what’s right to ensure that they are approved and on the right track towards providing exceptional services to their customers.
In particular, he said:
“Curaleaf is committed to being an ethical and responsible company and working with the FDA to be a leader in our industry, setting the standards and guidelines to best service our customers and the communities we serve.”
Here’s what the acting FDA Commissioner, Ned Sharpless said in a previous statement concerning this matter:
“Today’s action demonstrates that the agency stands firm in its commitment to continue monitoring the marketplace and protecting the public health by taking action as needed against companies that deceive consumers and put them at risk by illegally selling products marketed for therapeutic uses for which they are not approved.”